Cross-sectional analysis highlights serum irisin's role in distinguishing DR stages in T2DM patients, suggesting possible clinical implications.
Background: Diabetic retinopathy (DR) impairs retinal function and causes significant vision loss. Irisin has been recently implicated in the pathogenesis of DR. Intercellular adhesion molecule-1 (ICAM-1) is a cell surface glycoprotein that primarily facilitates leucocyte recruitment from circulation to inflammation sites. Aims: This cross-sectional study aimed to explore the significance of circulatory irisin and ICAM-1 levels in DR. Subjects and Methods: This cross-sectional analytical study was conducted at a tertiary care hospital in Puducherry, India. Type 2 diabetes mellitus (T2DM) patients with retinopathy ( n = 60) and without retinopathy ( n = 60) were recruited. Apart from anthropometric data, blood samples were collected for routine biochemical tests and estimation of serum irisin and ICAM-1 by ELISA. Data were analysed using IBM SPSS version 20.0. The variables were compared using Independent Student’s- t -test, Mann–Whitney U -test, one-way analysis of variance, or Chi-square test. Receiver operator curve (ROC) analysis evaluated irisin and ICAM-1 in differentiating proliferative DR (PDR) and non-proliferative DR (NPDR). Results: Compared to T2DM patients without DR, Serum irisin was higher in those with DR, but no difference was observed in ICAM-1 between the 2 groups. Both irisin and ICAM-1 were decreased in vision-threatening DR (VTDR) compared to non-vision-threatening DR (non-VTDR). Decreased levels of irisin ( P = 0.84) and ICAM-1 ( P ≤ 0.001) were seen across DR stages. ROC analysis showed irisin differentiated NPDR and PDR (AUC = 0.7, P = 0.01). Conclusions: Serum irisin and ICAM-1 increased in earlier stages of DR but decreased in later stages. They were decreased in pre-proliferative and proliferative stages of DR, suggesting roles in leucocyte migration and angiogenesis. Clinical management may have contributed, and further research is needed.
No takes yet. Share an insight, caveat, or question.
Sherwin et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: